Arteaga Lab | UT Southwestern, Dallas, Texas

Our focus is on translational breast cancer research, aimed at developing therapeutic strategies and identifying biomarkers of drug sensitivity and resistance.

The Arteaga Laboratory has a longstanding interest in understanding the molecular pathways that drive breast cancer progression and influence response to therapies.

View Our Research

Antiestrogen resistance biopsies under microscope

Antiestrogen resistance
Amplifications of FGFR1 (left) and CCND1 (right) are enriched in biopsies from letrozole-resistant breast cancers.

The HER2 T798I “gatekeeper” mutation mediates resistance to the HER2 inhibitor neratinib, but not afatinib.

High-throughput screening charts A and B

High-throughput screening
A kinome screen identifies FGFR1 as a mediator of resistance to the combination of an antiestrogen and CDK4/6 inhibitor.

Targetable alterations
Next-gen sequencing of residual triple-negative breast cancers after neoadjuvant chemotherapy reveals targetable alterations in the residual tumors.

Get Involved

Meet the Team

Get to know our Principal Investigator and team of researchers.

See Lab Members & Alumni

Collaborate

Interested in our research? Get in touch to learn more or find out ways to collaborate.

Get in Touch

Join Our Lab

If you're interested in joining our team, please reach out to learn more about open positions.

Explore Opportunities